Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764531 | 0.76 | BRD4 (0.52) | ATMPTGER4BRD4 | |
| SCHEMBL12632192 | 0.75 | BRD4 (0.62) | ATMPTGER4BRD4 | |
| SCHEMBL13834447 | 0.75 | BRD4 (0.62) | ATMPTGER4BRD4 | |
| SCHEMBL13834740 | 0.74 | BRD4 (0.48) | PTGER4BRD4KDM4E | |
| SCHEMBL2029083 | 0.74 | BRD4 (0.48) | PTGER4BRD4KDM4E | |
| SCHEMBL13834739 | 0.73 | BRD4 (0.51) | ATMPTGER4BRD4 | |
| SCHEMBL12630671 | 0.73 | BRD4 (0.51) | ATMPTGER4BRD4 | |
| SCHEMBL2035437 | 0.73 | BRD4 (0.50) | BRD4 | |
| SCHEMBL13834450 | 0.73 | BRD4 (0.50) | ATMPTGER4BRD4 | |
| SCHEMBL13835022 | 0.73 | BRD4 (0.50) | PTGER4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, COASY | ATM 3624/4885PTGER4 1801/4885BRD4 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.